Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit

• DOI: 10.1016/j.neulet.2004.10.062
• Publication Date: 2004-12-11T19:47:20Z
• Authors: Francisco Javier ...; Mónica García-Alloza; Jon Domínguez; Beatriz Marcos; María Javier Ramírez
• Keywords: Male; 0301 basic medicine; 03 medical and health sciences; Alzheimer Disease; Animals; Humans; Acetylcholine (ACh); N-Glycosyl Hydrolases; Acetylcholinesterase (AChE); Aged; Analysis of Variance; Cognitive deficit; Immunotoxins; Antibodies, Monoclonal; Brain; Acetylcholine; Cholinacetyltransferase (ChAT); Rats; 3. Good health; Disease Models, Animal; Case-Control Studies; Postmortem Changes; Acetylcholinesterase; Ribosome Inactivating Proteins, Type 1; Rat; Female; Mental Status Schedule; Biomarkers; Human

Cognitive deficits in neuropsychiatric disorders, such as Alzheimer's disease (AD), have been closely related to cholinergic deficits. We have compared different markers of cholinergic function to assess the best biomarker of cognitive deficits associated to cholinergic hypoactivity. In post-mortem frontal cortex from AD patients, acetylcholine (ACh) levels, cholinacetyltransferase (ChAT) and acetylcholinesterase (AChE) activity were all reduced compared to controls. Both ChAT and AChE activity showed a significant correlation with cognitive deficits. In the frontal cortex of rats with a selective cholinergic lesion, all cholinergic parameters measured (ACh levels, ChAT and AChE activities, "in vitro" and "in vivo" basal ACh release) were significantly reduced. AChE activity was associated to ChAT activity, and even more, to "in vivo" and "in vitro" basal ACh release. Quantification of AChE activity is performed by an easy and cheap method and therefore, these results suggest that determination of AChE activity may be used as an effective first step method to evaluate cholinergic deficits.